Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes early diagnosis of this rare, autoimmune disease important for developing an effective treatment plan and personalized treatment selection a key success factor in the optimization of patient care.
Decoding ANCA-Associated Vasculitis (AAV): From Suspicion to Solution
6
episodes
41m
Choose a format
Details
Presenters
Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Silke R. Brix, MD, MRCP, SCPR
NIHR Senior Clinician Practitioner Researcher
Consultant in Nephrology and Vasculitis, Manchester Royal Infirmary
Honorary Senior Lecturer, Manchester University
Manchester, United Kingdom
Dr. Brix has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: CSL Vifor, Roche
Bernhard Hellmich, MD
Chair, Department of Medicine
Medius Kliniken, University of Tübingen
Baden-Württemberg, Germany
Dr. Hellmich has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AbbVie, Astra Zeneca, Boehringer Ingelheim, CSL Vifor, GSK, InflaRx, Janssen, Novartis
Royalties: AbbVie, Amgen, BMS, Boehringer Ingelheim, CSL Vifor, GSK, InflaRx, Janssen, MSD, Novartis, Pfizer, Phadia, Roche
Andreas Kronbichler, MD
Assistant Professor of Medicine
Medical University of Innsbruck
Innsbruck, Austria
Dr. Kronbichler has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, CSL Vifor, Delta4, GSK, Otsuka
Contracted Research: CSL ViforReviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Anita Galdieri, PharmD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Katie Sheridan, PhD, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Implement a timely and comprehensive diagnostic approach for patients with suspected ANCA-associated vasculitis (AAV)
- Evaluate recent clinical practice guideline updates and their impact on the management of patients with AAV
- Develop personalized AAV induction and maintenance treatment plans to optimize patient outcomes
Target Audience
This activity has been designed to meet the educational needs of nephrologists, nephrology nurses, rheumatologists, and renal pathologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with AAV.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
